Form 4: Sarepta Therapeutics Executive Bilal Arif Reports Changes in Beneficial Ownership

Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports a transaction involving the disposal of shares to cover tax obligations and an acquisition through the Employee Stock Purchase Plan.

Summary

• On March 3, 2025, Sarepta Therapeutics' Chief Tech Ops Officer, Bilal Arif, reported changes in beneficial ownership of the company's common stock.
• 719 shares were disposed of to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 1, 2024.
• The shares were sold at a price of $103.77 per share.
• Arif also acquired 152 shares through the company's Employee Stock Purchase Plan on February 28, 2025.
• Following these transactions, Arif beneficially owns 16,796 shares of Sarepta Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and does not indicate any significant positive or negative developments.

Positives

• Arif's participation in the Employee Stock Purchase Plan indicates confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to tax obligations and employee stock purchase plan.

Key Dates